What Are the Most Common Uses of Abiraterone Acetate?
Abiraterone acetate is a CYP17 inhibitor suitable for use in combination with prednisone for the treatment of patients with metastatic castration-refractory prostate cancer who have received docetaxel-containing chemotherapy.
Abiraterone acetate
Right!
- Abiraterone acetate is a CYP17
- Abiraterone acetate
- [Other names]: ZYTIGA
- Abiraterone acetate is a CYP17 inhibitor suitable for use in combination with prednisone for the treatment of patients with metastatic castration-refractory prostate cancer who have received docetaxel-containing chemotherapy.
- Dosage and Administration
- ZYTIGA 1,000 mg orally once daily in combination with prednisone 5 mg orally twice daily. ZYTIGA must be taken on an empty stomach. Food should not be consumed at least 2 hours before taking the ZYTIGA dose and at least 1 hour after taking the ZYTIGA dose.
- (1) For patients with baseline moderate liver impairment (Child-Pugh category B), reduce the starting dose of ZYTIGA to 250 mg once daily.
- (2) For patients who develop liver toxicity during treatment, do not use ZYTIGA until recovery. Can be re-treated at a reduced dose. ZYTIGA should be discontinued if the patient develops severe liver toxicity.
- Dosage form and specifications
- 250 mg / tablet
- Contraindications
- ZYTIGA is contraindicated in pregnant women who may become pregnant.
- Warnings and cautions
- (1) Mineralocorticoid overdose: Use ZYTIGA with caution in patients with a history of cardiovascular disease. The safety of ZYTIGA in patients with LVEF <50% or NYHA Class III or IV heart failure has not been established. Control hypertension and correct hypokalemia before treatment. Monitor blood pressure, serum potassium and fluid retention at least once a month.
- (2) Adrenal insufficiency: Monitor the symptoms and signs of adrenal insufficiency. Increased corticosteroid dose may be adapted before, during, and after an emergency.
- (3) Hepatotoxicity: Increased liver enzymes have caused drug discontinuation, dose adjustment and / or termination. Monitor liver function and adjust, discontinue or discontinue ZYTIGA administration as recommended.
- (4) Food effects: ZYTIGA must be taken on an empty stomach. When taking abiraterone acetate with food at the same time, the exposure (area under the curve) increased by 10 times.
- Adverse reactions
- The most common adverse reactions ( 5%) are swelling or discomfort in the joints, hypokalemia, edema, muscle discomfort, hot flushes, diarrhea, urinary tract infections, cough, hypertension, arrhythmia, frequent urination, nocturia, indigestion, And upper respiratory tract infections.
- medicine interactions
- ZYTIGA is a liver drug metabolizing enzyme CYP2D6 is an inhibitor. Co-administration of ZYTIGA with CYP2D6 substrate is avoided due to the narrow therapeutic index. If additional treatment cannot be used, be careful and consider reducing the concurrent CYP2D6 substrate dose.